A Phase 2 interventional study of adalimumab in Rheumatoid Arthritis, sponsored by Abbott. Completed at 7 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2011-04-11.
Sponsored by Abbott · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 79th largest by enrollment, is one of 6 that started in 2003, is one of 9 in phase 2, and was the 12th registered.
3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 6 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
33 studies in Arthritis, Rheumatoid by Abbott: none open now, none under way, none of them phase 3. Of 30 finished, 19 (63%) have results posted.
Among the 33 studies in Arthritis, Rheumatoid by Abbott, this one is the 21st largest by enrollment of the 22 interventional ones that give a count, is one of 7 that started in 2003, is the only one in phase 2, and was the 10th registered.
Abbott’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 33 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the long-term safety, tolerability, and efficacy of repeated administration of adalimumab in adult Japanese subjects with rheumatoid arthritis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A subject who experienced any of the following during the prior adalimumab sc dosing study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: adalimumab
40 mg every other week (eow), subcutaneous (sc)
Also known as: ABT-D2E7, Humira
Number of Responders With American College of Rheumatology (ACR) Criteria Improvement of at Least 20%, 50%, and 70% (ACR 20/50/70 Responders)
Number of subjects with American College of Rheumatology (ACR) criteria improvement consisting of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) reduction in tender or swollen joint counts \[TJC or SJC, respectively\] and 20%, 50%, and 70% improvement, respectively, in 3 of the following 5 criteria: \[1\] physician's global assessment of disease activity \[PGA\], \[2\] subject's assessment of disease activity, \[3\] subject's assessment of pain, \[4\] subject's assessment of functional disability via a health assessment questionnaire \[HAQ\], and \[5\] C-reactive protein \[CRP\]) at each visit
Time frame: Every 6 weeks up to Week 24 and every 12 weeks thereafter up to study completion or discontinuation (final value)
Mean Change From Baseline in Tender Joint Count (TJC, Max = 68), a Component of the ACR Criteria, by Visit
Mean change from baseline (last assessment in preceding study prior to adalimumab injection) in tender joint count (TJC, max = 68), a component of the ACR criteria, by visit
Time frame: Every 6 weeks up to Week 24 and every 12 weeks thereafter up to study completion or discontinuation (final value)
Mean Change From Baseline in Swollen Joint Count (SJC, Max = 66), a Component of the ACR Criteria, by Visit
Mean change from baseline(last assessment in preceding study prior to adalimumab injection) in the SJC (max = 66) component of the ACR criteria
Time frame: Every 6 weeks up to Week 24 and every 12 weeks thereafter up to study completion or discontinuation (final value)
Mean Change From Baseline in Physician's Global Assessment of Disease Activity (PGA) Using a Visual Analog Scale (0 - 100 mm With 100 mm Being the Worst Possible Assessment), a Component of the ACR Criteria, by Visit
Mean change from baseline (last assessment in preceding study prior to adalimumab injection) in PGA (a visual analog scale from 0 - 100 mm with 100 mm being the worst possible assessment), a component of the ACR criteria, by visit.
Time frame: Every 6 weeks up to Week 24 and every 12 weeks thereafter up to study completion or discontinuation (final value)
Mean Change From Baseline in Subject's Global Assessment of Disease Activity Using a Visual Analog Scale (0 - 100 mm With 100 mm Being the Worst Possible Assessment), a Component of the ACR Criteria, by Visit
Mean change from baseline (last assessment in preceding study prior to adalimumab injection) in subject's global assessment of disease activity (a visual analog scale from 0 - 100 mm with 100 mm being the worst case), a component of the ACR criteria, by visit
Time frame: Every 6 weeks up to Week 24 and every 12 weeks thereafter up to study completion or discontinuation (final value)
Mean Change From Baseline (Last Assessment in Preceding Study Prior to Adalimumab Injection) in Subject's Assessment of Pain Using a Visual Analog Scale (0 - 100 mm With 100 mm Being the Worst Possible Pain), a Component of the ACR Criteria, by Visit
Mean change from baseline (last assessment in preceding study prior to adalimumab injection) in subject's assessment of pain (using a visual analog scale from 0 - 100 mm with 100 mm being the worst possible pain), a component of the ACR criteria, by visit
Time frame: Every 6 weeks up to Week 24 and every 12 weeks thereafter up to study completion or discontinuation (final value)
Mean Change From Baseline in Disability Index of the Health Assessment Questionnaire [HAQ], a Component the of ACR Criteria, by Visit
Mean change from baseline (last assessment in preceding study prior to adalimumab injection) in disability index of the health assessment questionnaire \[HAQ; includes 20 questions assessing physical function in 8 domains. The questions are evaluated on a scale from 0 - 3 to measure the ability to perform certain activities (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do so).\], a component the of ACR criteria, by visit
Time frame: Every 6 weeks up to Week 24 and every 12 weeks thereafter up to study completion or discontinuation (final value)
Mean Change From Baseline in C-reactive Protein [CRP; mg/dL], a Component of the ACR Criteria, by Visit.
Mean change from baseline (last assessment in preceding study prior to adalimumab injection) in C-reactive protein \[CRP; mg/dL\], a component of the ACR criteria, by visit.
Time frame: Every 6 weeks up to Week 24 and every 12 weeks thereafter up to study completion or discontinuation (final value)
Area Under the Curve (AUC; From Start of the Study to Each Study Visit) of Subjects' Who Improved at Least 20% in ACR Response Criteria (ACR20 Response)
Sum of the duration (from start of study to each study visit) when a subject with American College of Rheumatology (ACR) criteria improved by 20% (ACR20) in tender or swollen joint counts \[TJC or SJC, respectively\] and 20% improvement in 3 of the following 5 criteria: \[1\] Physician's global assessment (PGA), \[2\] subject's assessment of disease activity, \[3\] subject's assessment of pain, \[4\] subject's assessment of functional disability via a health assessment questionnaire \[HAQ\], and \[5\] C-reactive protein (CRP)
Time frame: Every 6 weeks up to Week 24 and every 12 weeks thereafter
Number of Subjects With Morning Stiffness at Each Visit
The number of subjects with morning stiffness (assessed as present or absent) at each visit among those who had morning stiffness at baseline (21).
Time frame: Every 6 weeks up to Week 24 and every 12 weeks thereafter up to study completion or discontinuation (final value)
Japanese subjects with moderate to severe rheumatoid arthritis (RA) in relatively good physical health excluding RA symptoms and who completed a preceding continuous repeated administration study of adalimumab (DE035X/D2E7-J081-003) who wished to continue treatment until approval of adalimumab in Japan.
| Milestone | Adalimumab 40 mg Eow |
|---|---|
| Started | 25 |
| Completed | 9 |
| Not completed | 16 |
Number of subjects with American College of Rheumatology (ACR) criteria improvement consisting of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) reduction in tender or swollen joint counts \[TJC or SJC, respectively\] and 20%, 50%, and 70% improvement, respectively, in 3 of the following 5 criteria: \[1\] physician's global assessment of disease activity \[PGA\], \[2\] subject's assessment of disease activity, \[3\] subject's assessment of pain, \[4\] subject's assessment of functional disability via a health assessment questionnaire \[HAQ\], and \[5\] C-reactive protein \[CRP\]) at each visit
| participants | Adalimumab 40 mg Eow |
|---|---|
| Week 0 ACR20 | 12 |
| Week 0 ACR50 | 7 |
| Week 0 ACR70 | 5 |
| Week 6 ACR20 | 15 |
| Week 6 ACR50 | 12 |
| Week 6 ACR70 | 5 |
| Week 12 ACR20 | 16 |
| Week 12 ACR50 | 11 |
| Week 12 ACR70 | 6 |
| Week 18 ACR20 | 18 |
| Week 18 ACR50 | 11 |
| Week 18 ACR70 | 7 |
| Week 24 ACR20 | 16 |
| Week 24 ACR50 | 11 |
| Week 24 ACR70 | 4 |
| Week 36 ACR20 | 15 |
| Week 36 ACR50 | 10 |
| Week 36 ACR70 | 6 |
| Week 48 ACR20 | 13 |
| Week 48 ACR50 | 10 |
| Week 48 ACR70 | 5 |
| Week 60 ACR20 | 12 |
| Week 60 ACR50 | 11 |
| Week 60 ACR70 | 6 |
| Week 72 ACR20 | 11 |
| Week 72 ACR50 | 10 |
| Week 72 ACR70 | 3 |
| Week 84 ACR20 | 11 |
| Week 84 ACR50 | 9 |
| Week 84 ACR70 | 7 |
| Week 96 ACR20 | 11 |
| Week 96 ACR50 | 10 |
| Week 96 ACR70 | 6 |
| Week 108 ACR20 | 11 |
| Week 108 ACR50 | 10 |
| Week 108 ACR70 | 6 |
| Week 120 ACR20 | 10 |
| Week 120 ACR50 | 10 |
| Week 120 ACR70 | 6 |
| Week 132 ACR20 | 10 |
| Week 132 ACR50 | 7 |
| Week 132 ACR70 | 5 |
| Week 144 ACR20 | 10 |
| Week 144 ACR50 | 9 |
| Week 144 ACR70 | 7 |
| Week 156 ACR20 | 9 |
| Week 156 ACR50 | 8 |
| Week 156 ACR70 | 4 |
| Week 168 ACR20 | 9 |
| Week 168 ACR50 | 8 |
| Week 168 ACR70 | 6 |
| Week 180 ACR20 | 10 |
| Week 180 ACR50 | 9 |
| Week 180 ACR70 | 5 |
| Week 192 ACR20 | 9 |
| Week 192 ACR50 | 8 |
| Week 192 ACR70 | 5 |
| Week 204 ACR20 | 10 |
| Week 204 ACR50 | 8 |
| Week 204 ACR70 | 4 |
| Week 216 ACR20 | 9 |
| Week 216 ACR50 | 8 |
| Week 216 ACR70 | 4 |
| Week 228 ACR20 | 9 |
| Week 228 ACR50 | 7 |
| Week 228 ACR70 | 3 |
| Week 240 ACR20 | 7 |
| Week 240 ACR50 | 4 |
| Week 240 ACR70 | 1 |
| Week 252 ACR20 | 5 |
| Week 252 ACR50 | 3 |
| Week 252 ACR70 | 2 |
| Week 264 ACR20 | 2 |
| Week 264 ACR50 | 1 |
| Week 264 ACR70 | 1 |
| Final Value ACR20 | 13 |
| Final Value ACR50 | 11 |
| Final Value ACR70 | 8 |
Mean change from baseline (last assessment in preceding study prior to adalimumab injection) in tender joint count (TJC, max = 68), a component of the ACR criteria, by visit
| TJC | Adalimumab 40 mg Eow |
|---|---|
| Week 0 | -11.2 ± 14.5 |
| Week 6 | -13.4 ± 11.2 |
| Week 12 | -16.0 ± 14.0 |
| Week 18 | -17.5 ± 12.2 |
| Week 24 | -16.3 ± 13.7 |
| Week 36 | -17.0 ± 13.4 |
| Week 48 | -18.1 ± 13.8 |
| Week 60 | -18.5 ± 13.2 |
| Week 72 | -18.1 ± 13.2 |
| Week 84 | -21.9 ± 13.7 |
| Week 96 | -22.8 ± 13.6 |
| Week 108 | -21.8 ± 13.6 |
| Week 120 | -22.7 ± 14.4 |
| Week 132 | -22.0 ± 14.5 |
| Week 144 | -21.2 ± 14.4 |
| Week 156 | -22.1 ± 14.9 |
| Week 168 | -22.7 ± 13.6 |
| Week 180 | -22.7 ± 13.5 |
| Week 192 | -23.3 ± 14.5 |
| Week 204 | -23.1 ± 14.7 |
| Week 216 | -23.7 ± 14.7 |
| Week 228 | -23.4 ± 14.7 |
| Week 240 | -24.6 ± 13.7 |
| Week 252 | -26.7 ± 17.5 |
| Week 264 | -25.0 ± 7.1 |
| Final Value | -15.8 ± 13.8 |
Mean change from baseline(last assessment in preceding study prior to adalimumab injection) in the SJC (max = 66) component of the ACR criteria
| SJC | Adalimumab 40 mg Eow |
|---|---|
| Week 0 | -8.8 ± 11.0 |
| Week 6 | -11.3 ± 11.3 |
| Week 12 | -12.0 ± 12.1 |
| Week 18 | -14.4 ± 9.6 |
| Week 24 | -13.8 ± 10.7 |
| Week 36 | -12.4 ± 6.8 |
| Week 48 | -14.9 ± 6.3 |
| Week 60 | -14.8 ± 5.7 |
| Week 72 | -14.5 ± 6.5 |
| Week 84 | -13.5 ± 4.7 |
| Week 96 | -13.9 ± 5.8 |
| Week 108 | -13.8 ± 5.7 |
| Week 120 | -13.2 ± 4.5 |
| Week 132 | -13.2 ± 4.2 |
| Week 144 | -14.0 ± 3.9 |
| Week 156 | -13.3 ± 4.3 |
| Week 168 | -13.2 ± 5.5 |
| Week 180 | -13.7 ± 4.4 |
| Week 192 | -13.4 ± 4.9 |
| Week 204 | -12.9 ± 5.3 |
| Week 216 | -12.6 ± 5.8 |
| Week 228 | -12.9 ± 5.5 |
| Week 240 | -11.8 ± 5.8 |
| Week 252 | -11.8 ± 5.8 |
| Week 264 | -12.0 ± 8.5 |
| Final Value | -10.1 ± 11.8 |
Mean change from baseline (last assessment in preceding study prior to adalimumab injection) in PGA (a visual analog scale from 0 - 100 mm with 100 mm being the worst possible assessment), a component of the ACR criteria, by visit.
| mm on scale | Adalimumab 40 mg Eow |
|---|---|
| Week 0 | -27.0 ± 28.6 |
| Week 6 | -34.5 ± 28.4 |
| Week 12 | -40.7 ± 22.0 |
| Week 18 | -42.2 ± 22.1 |
| Week 24 | -41.3 ± 24.2 |
| Week 36 | -34.3 ± 19.9 |
| Week 48 | -40.7 ± 21.7 |
| Week 60 | -39.2 ± 27.8 |
| Week 72 | -39.2 ± 26.7 |
| Week 84 | -40.1 ± 29.8 |
| Week 96 | -51.7 ± 20.9 |
| Week 108 | -50.6 ± 20.6 |
| Week 120 | -50.5 ± 27.3 |
| Week 132 | -50.1 ± 21.1 |
| Week 144 | -43.6 ± 28.1 |
| Week 156 | -47.2 ± 28.9 |
| Week 168 | -49.5 ± 25.6 |
| Week 180 | -51.8 ± 24.4 |
| Week 192 | -49.6 ± 26.7 |
| Week 204 | -47.5 ± 22.7 |
| Week 216 | -52.5 ± 22.8 |
| Week 228 | -49.5 ± 23.2 |
| Week 240 | -47.3 ± 18.9 |
| Week 252 | -51.7 ± 23.5 |
| Week 264 | -35.5 ± 38.9 |
| Final Value | -31.2 ± 32.7 |
Mean change from baseline (last assessment in preceding study prior to adalimumab injection) in subject's global assessment of disease activity (a visual analog scale from 0 - 100 mm with 100 mm being the worst case), a component of the ACR criteria, by visit
| mm on scale | Adalimumab 40 mg Eow |
|---|---|
| Week 0 | -21.7 ± 27.4 |
| Week 6 | -29.5 ± 25.8 |
| Week 12 | -33.3 ± 25.8 |
| Week 18 | -35.1 ± 25.7 |
| Week 24 | -35.6 ± 22.2 |
| Week 36 | -33.0 ± 24.5 |
| Week 48 | -38.3 ± 24.3 |
| Week 60 | -38.7 ± 26.4 |
| Week 72 | -39.3 ± 24.9 |
| Week 84 | -37.1 ± 30.3 |
| Week 96 | -42.9 ± 26.0 |
| Week 108 | -35.1 ± 31.0 |
| Week 120 | -40.4 ± 26.2 |
| Week 132 | -34.1 ± 21.3 |
| Week 144 | -37.3 ± 26.4 |
| Week 156 | -34.5 ± 31.1 |
| Week 168 | -37.2 ± 26.3 |
| Week 180 | -36.1 ± 20.4 |
| Week 192 | -35.3 ± 26.1 |
| Week 204 | -35.0 ± 18.0 |
| Week 216 | -30.3 ± 23.9 |
| Week 228 | -30.7 ± 27.6 |
| Week 240 | -23.9 ± 22.4 |
| Week 252 | -25.0 ± 21.2 |
| Week 264 | -19.5 ± 10.6 |
| Final Value | -20.0 ± 27.9 |
Mean change from baseline (last assessment in preceding study prior to adalimumab injection) in subject's assessment of pain (using a visual analog scale from 0 - 100 mm with 100 mm being the worst possible pain), a component of the ACR criteria, by visit
| mm on scale | Adalimumab 40 mg Eow |
|---|---|
| Week 0 | -13.7 ± 31.6 |
| Week 6 | -23.1 ± 24.7 |
| Week 12 | -27.2 ± 27.3 |
| Week 18 | -29.1 ± 28.2 |
| Week 24 | -30.6 ± 20.2 |
| Week 36 | -26.2 ± 28.2 |
| Week 48 | -32.7 ± 22.2 |
| Week 60 | -33.4 ± 26.1 |
| Week 72 | -33.4 ± 24.2 |
| Week 84 | -32.9 ± 26.7 |
| Week 96 | -37.6 ± 22.7 |
| Week 108 | -31.8 ± 27.6 |
| Week 120 | -35.0 ± 21.9 |
| Week 132 | -30.0 ± 18.6 |
| Week 144 | -33.1 ± 24.1 |
| Week 156 | -29.9 ± 31.0 |
| Week 168 | -31.8 ± 24.0 |
| Week 180 | -32.8 ± 19.8 |
| Week 192 | -31.0 ± 23.4 |
| Week 204 | -30.6 ± 17.4 |
| Week 216 | -24.4 ± 23.7 |
| Week 228 | -26.5 ± 26.8 |
| Week 240 | -24.9 ± 23.7 |
| Week 252 | -20.3 ± 24.4 |
| Week 264 | -7.0 ± 2.8 |
| Final Value | -14.4 ± 29.6 |
Mean change from baseline (last assessment in preceding study prior to adalimumab injection) in disability index of the health assessment questionnaire \[HAQ; includes 20 questions assessing physical function in 8 domains. The questions are evaluated on a scale from 0 - 3 to measure the ability to perform certain activities (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do so).\], a component the of ACR criteria, by visit
| units on a scale | Adalimumab 40 mg Eow |
|---|---|
| Week 0 | -0.41 ± 0.77 |
| Week 6 | -0.48 ± 0.64 |
| Week 12 | -0.47 ± 0.65 |
| Week 18 | -0.50 ± 0.72 |
| Week 24 | -0.49 ± 0.76 |
| Week 36 | -0.43 ± 0.77 |
| Week 48 | -0.63 ± 0.72 |
| Week 60 | -0.66 ± 0.81 |
| Week 72 | -0.73 ± 0.81 |
| Week 84 | -0.82 ± 0.71 |
| Week 96 | -0.80 ± 0.71 |
| Week 108 | -0.74 ± 0.83 |
| Week 120 | -0.73 ± 0.81 |
| Week 132 | -0.63 ± 0.80 |
| Week 144 | -0.63 ± 0.80 |
| Week 156 | -0.58 ± 0.69 |
| Week 168 | -0.64 ± 0.78 |
| Week 180 | -0.63 ± 0.70 |
| Week 192 | -0.49 ± 0.73 |
| Week 204 | -0.51 ± 0.67 |
| Week 216 | -0.51 ± 0.77 |
| Week 228 | -0.49 ± 0.93 |
| Week 240 | -0.36 ± 0.70 |
| Week 252 | -0.25 ± 0.80 |
| Week 264 | 0.25 ± 1.41 |
| Final Value | -0.31 ± 0.77 |
Mean change from baseline (last assessment in preceding study prior to adalimumab injection) in C-reactive protein \[CRP; mg/dL\], a component of the ACR criteria, by visit.
| mg/dL | Adalimumab 40 mg Eow |
|---|---|
| Week 0 | -0.92 ± 2.64 |
| Week 6 | -2.30 ± 2.73 |
| Week 12 | -2.49 ± 3.55 |
| Week 18 | -2.11 ± 3.22 |
| Week 24 | -2.62 ± 2.49 |
| Week 36 | -2.42 ± 3.17 |
| Week 48 | -2.94 ± 3.37 |
| Week 60 | -3.31 ± 3.15 |
| Week 72 | -3.05 ± 3.35 |
| Week 84 | -2.84 ± 3.50 |
| Week 96 | -3.37 ± 3.08 |
| Week 108 | -3.07 ± 3.09 |
| Week 120 | -3.16 ± 3.62 |
| Week 132 | -3.23 ± 3.39 |
| Week 144 | -3.14 ± 3.66 |
| Week 156 | 0.01 ± 10.96 |
| Week 168 | -3.47 ± 3.42 |
| Week 180 | -3.49 ± 3.28 |
| Week 192 | -3.21 ± 3.42 |
| Week 204 | -3.30 ± 3.22 |
| Week 216 | -2.90 ± 2.57 |
| Week 228 | -2.93 ± 2.57 |
| Week 240 | -1.71 ± 6.10 |
| Week 252 | -1.89 ± 3.56 |
| Week 264 | -4.16 ± 5.35 |
| Final Value | -1.14 ± 4.23 |
Sum of the duration (from start of study to each study visit) when a subject with American College of Rheumatology (ACR) criteria improved by 20% (ACR20) in tender or swollen joint counts \[TJC or SJC, respectively\] and 20% improvement in 3 of the following 5 criteria: \[1\] Physician's global assessment (PGA), \[2\] subject's assessment of disease activity, \[3\] subject's assessment of pain, \[4\] subject's assessment of functional disability via a health assessment questionnaire \[HAQ\], and \[5\] C-reactive protein (CRP)
| Weeks | Adalimumab 40 mg Eow |
|---|---|
| Week 0 - Week 6 | 3.2 ± 2.7 |
| Week 0 - Week 12 | 7.0 ± 5.5 |
| Week 0 - Week 18 | 11.0 ± 8.0 |
| Week 0 - Week 24 | 15.1 ± 10.6 |
| Week 0 - Week 36 | 22.6 ± 15.9 |
| Week 0 - Week 48 | 29.3 ± 21.1 |
| Week 0 - Week 60 | 35.3 ± 26.3 |
| Week 0 - Week 72 | 40.8 ± 31.3 |
| Week 0 - Week 84 | 46.1 ± 36.2 |
| Week 0 - Week 96 | 51.4 ± 41.3 |
| Week 0 - Week 108 | 56.6 ± 46.7 |
| Week 0 - Week 120 | 61.7 ± 52.0 |
| Week 0 - Week 132 | 66.5 ± 57.2 |
| Week 0 - Week 144 | 71.3 ± 62.5 |
| Week 0 - Week 156 | 75.8 ± 67.7 |
| Week 0 - Week 168 | 80.2 ± 72.7 |
| Week 0 - Week 180 | 84.7 ± 78.0 |
| Week 0 - Week 192 | 89.3 ± 83.4 |
| Week 0 - Week 204 | 93.8 ± 88.2 |
| Week 0 - Week 216 | 98.4 ± 92.7 |
| Week 0 - Week 228 | 102.7 ± 97.1 |
| Week 0 - Week 240 | 106.6 ± 101.0 |
| Week 0 - Week 252 | 109.4 ± 104.2 |
| Week 0 - Week 264 | 111.1 ± 106.4 |
The number of subjects with morning stiffness (assessed as present or absent) at each visit among those who had morning stiffness at baseline (21).
| participants | Adalimumab 40 mg Eow |
|---|---|
| Week 0 | 16 |
| Week 6 | 15 |
| Week 12 | 11 |
| Week 18 | 11 |
| Week 24 | 9 |
| Week 36 | 10 |
| Week 48 | 6 |
| Week 60 | 5 |
| Week 72 | 7 |
| Week 84 | 6 |
| Week 96 | 4 |
| Week 108 | 4 |
| Week 120 | 3 |
| Week 132 | 3 |
| Week 144 | 3 |
| Week 156 | 3 |
| Week 168 | 2 |
| Week 180 | 2 |
| Week 192 | 3 |
| Week 204 | 4 |
| Week 216 | 3 |
| Week 228 | 3 |
| Week 240 | 3 |
| Week 252 | 2 |
| Week 264 | 1 |
| Final Value | 15 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab 40 mg Eow | — | 10/25 (40%) | 25/25 (100%) |
| Event | Adalimumab 40 mg Eow |
|---|---|
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 3/25 |
| LymphadenitisBlood and lymphatic system disorders | 1/25 |
| Brugada syndromeCardiac disorders | 1/25 |
| PyrexiaGeneral disorders | 1/25 |
| PyelonephritisInfections and infestations | 1/25 |
| SepsisInfections and infestations | 1/25 |
| Tendon ruptureInjury, poisoning and procedural complications | 1/25 |
| C-reactive protein increasedInvestigations | 1/25 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/25 |
| Metastases to lymph nodesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/25 |
| Event | Adalimumab 40 mg Eow |
|---|---|
| NasopharyngitisInfections and infestations | 15/25 |
| DiarrhoeaGastrointestinal disorders | 6/25 |
| PruritusSkin and subcutaneous tissue disorders | 5/25 |
| Adverse drug reactionGeneral disorders | 4/25 |
| Hepatic function abnormalHepatobiliary disorders | 4/25 |
| CystitisInfections and infestations | 4/25 |
| ContusionInjury, poisoning and procedural complications | 4/25 |
| Back painMusculoskeletal and connective tissue disorders | 4/25 |
| InsomniaPsychiatric disorders | 4/25 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 4/25 |
| Age Continuous(years) | Adalimumab 40 mg Eow |
|---|---|
| Mean | 54.1 ± 11.1 |
| Sex: Female, Male(Participants) | Adalimumab 40 mg Eow |
|---|---|
| Female | 21 |
| Male | 4 |
| Region of Enrollment(participants) | Adalimumab 40 mg Eow |
|---|---|
| Japan | 25 |
The record gives a start of Jun 2003 and a primary completion of Oct 2004. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 5 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab